

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



MRVI1 siRNA (h): sc-42928



The Power to Question

BACKGROUND

The integration of the murine leukemia virus (MuLV) into the mammalian genome is frequently associated with insertional mutagenesis of cellular proto-oncogenes and tumor suppressor genes leading to cellular transformation and leukemias. Several proto-oncogenes were initially identified as sites of viral integration, including the tumor-suppressors Myc, Myb, and Hox. A related murine virus, MRV, also induces leukemia through viral integration and the disruption of the MRVI1 encoding gene. MRVI1 is specifically expressed in megakaryocytes and various myeloid leukemias, and its expression is downregulated during monocytic differentiation. The human and murine homologs of MRVI1 share substantial sequence similarity and similar expression patterns and are most closely related to the lymphoid specific protein Jaw1. The transcripts generated from MRVI1 are alternatively spliced and initiated from two distinct promoters to produce a longer isoform, MRVI1a, which contains an N-terminal 84 amino acid extension that is not present in the otherwise identical, shorter isoform, MRVI1b. These two isoforms have distinct subcellular localization patterns as MRVI1a contains an additional transmembrane domain and localizes to the endoplasmic recticulum, while MRVI1b is diffusely distributed throughout the cell.

REFERENCES

- 1. Bowerman, B., et al. 1989. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev. 3: 469-478.
- Buchberg, A.M., et al. 1990. Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol. Cell. Biol. 10: 4658-4666.
- Cho, B.C., et al. 1995. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J. Virol. 69: 7138-7146.
- 4. Moskow, J.J., et al. 1995. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol. Cell. Biol. 15: 5434-5443.
- 5. Shaughnessy, J.D., Jr., et al. 1999. MRV11, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1. Oncogene 18: 2069-2084.

CHROMOSOMAL LOCATION

Genetic locus: MRVI1 (human) mapping to 11p15.4.

PRODUCT

MRVI1 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MRVI1 shRNA Plasmid (h): sc-42928-SH and MRVI1 shRNA (h) Lentiviral Particles: sc-42928-V as alternate gene silencing products.

For independent verification of MRVI1 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-42928A, sc-42928B and sc-42928C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20 $^{\circ}$ C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20 $^{\circ}$ C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MRVI1 siRNA (h) is recommended for the inhibition of MRVI1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MRVI1 gene expression knockdown using RT-PCR Primer: MRVI1 (h)-PR: sc-42928-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**